Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMP962
- Development stage
- Preclinical
- Lead developer
- Amplia Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AMP962 is a preclinical-stage small molecule inhibitor of focal adhesion kinase (FAK) being developed by Amplia Therapeutics. It is designed to target FAK, a non-receptor tyrosine kinase that is frequently overexpressed in various cancers and plays a critical role in fibrotic diseases and tumor microenvironment remodeling. Preclinical studies have demonstrated that AMP962 effectively reduces pY397-FAK levels in ovarian cancer cells in vitro and shows therapeutic efficacy in ovarian cancer xenograft models (such as TOV-21G). The drug is being investigated for the treatment of fibrotic diseases and cancers, including ovarian cancer.
02
Targets
FAK (Focal adhesion kinase)
Beyond the preview
Go deeper on AMP962.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMP962.